about
Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney diseaseCardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular DiseaseVascular calcification: When should we interfere in chronic kidney disease patients and how?Phosphate binders in chronic kidney disease: a systematic review of recent data.Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.The use of fibroblast growth factor 23 testing in patients with kidney disease.Phosphate metabolism modulation in chronic kidney disease: when, how and to what extent?Effect of niacin on FGF23 concentration in chronic kidney disease.Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover studySevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.Endothelial nitric oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney disease.Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.Con: Phosphate binders in chronic kidney diseaseThe role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.Optimal use of phosphate binders in chronic kidney disease.Cardiovascular disease in CKD in 2013: Reducing cardiovascular risk--light at the end of the tunnel.Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond?Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.Influence of chronic kidney disease on cardiac structure and function.The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?Fibroblast Growth Factor 23: Mineral Metabolism and Beyond.Phosphate binders in patients with chronic kidney disease.Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease.Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.Cardiac Remodelling in Patients Undergoing in-Centre Nocturnal Haemodialysis: Results from the MIDNIGHT Study, a Non-Randomized Controlled Trial.Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).Optimal phosphate control: still an unmet need in chronic kidney disease patientsRenal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD
P2860
Q26863412-2B5105F4-C7AD-406E-922C-04E79C81E4D8Q27024043-268FA060-ADA6-4079-9174-A12122FD0112Q28071582-F2676F4C-7861-4E9F-9C66-9BAA100FB779Q31039292-1B969FD9-3BBA-4B7B-AD48-BAF025BA6A26Q33715785-86D8040D-D60F-4CAB-ACC0-49A0555659B5Q33791650-6438A66C-9C72-41D1-ADB7-2E054E23776FQ33835743-A5C7B268-4EB8-4F97-B799-F33E63951EB4Q33877167-458F0EC7-D153-4480-B5D0-1BBBDF93606CQ33914268-EA6AF21C-B73F-4423-BE9D-82D9F55AE0BBQ34037021-D57BF16C-D681-4CF9-9E68-54250810EF00Q34336027-37DE00AF-59D9-4B91-90EB-4CBA4746849FQ34505136-B6207718-0405-4489-A334-B74EC5F96B54Q35001614-4AFEC92F-948B-4D91-A327-65A4E92F8555Q35550601-CDE4C71A-A803-4403-B2D0-4595510397C4Q36104887-F9976500-E38D-4BFB-A1B0-1804CEB1A975Q36497902-469CDAA0-998D-4DBF-BB88-68AC084EC1ABQ36963471-AE2AE019-ECB4-4E8A-916D-E4C385A81F36Q38161580-5E065224-5ABB-4378-A6AB-C68560B23778Q38169970-E4CE8877-1F62-475B-A7CA-289F271AE151Q38185277-A09C32AE-1B86-4B77-B21D-6C0B3FC73493Q38200883-9E2166E9-9F47-4453-A172-99CD2F5D93E4Q38210438-1A659FB0-746B-4B28-AA55-BBD85446F436Q38550979-9DB5E638-CB86-4D3F-8A50-09BAB1C65045Q38584122-5BC80CCF-6CB9-46CA-9C58-A76B6AF75E50Q38673170-ECB18C80-3897-4687-B23E-7EC9F093AB75Q38768746-10B1A164-8F20-4162-AC31-5B7E6C04859AQ39155279-FEE20E95-2664-4248-9A13-E98592F55B19Q40471430-4E25B641-B4C5-49DB-AB7D-C897E8A34F2CQ48226016-0A297ED3-FFAF-4607-B66C-97A2FEE338D7Q50223912-456701B1-2CF3-4A71-B47C-12B74C722735Q54306096-BA14DAA1-99DA-48D2-9DDE-5CFE35236766Q55476982-61F50F7F-35E5-4E84-86F3-4C7E7C53A37DQ57217288-055C9E82-D7D7-4067-83C9-1165F6554799Q57823250-DB7D6EBF-6433-4C84-8E5B-931950AEDDBB
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cardiovascular effects of sevelamer in stage 3 CKD.
@en
type
label
Cardiovascular effects of sevelamer in stage 3 CKD.
@en
prefLabel
Cardiovascular effects of sevelamer in stage 3 CKD.
@en
P2093
P2860
P356
P1476
Cardiovascular effects of sevelamer in stage 3 CKD
@en
P2093
Colin D Chue
Daniel Zehnder
Lorraine Harper
Nadezhda A Wall
Nicola C Edwards
Richard P Steeds
William E Moody
P2860
P304
P356
10.1681/ASN.2012070719
P577
2013-04-18T00:00:00Z